Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Sjogren's Disease
Interventions
DRUG

Administration of Lotemax

An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.

Trial Locations (1)

14642

Flaum Eye Institute at the University of Rochester, Rochester

All Listed Sponsors
collaborator

Bausch & Lomb Incorporated

INDUSTRY

lead

University of Rochester

OTHER

NCT02322528 - Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax | Biotech Hunter | Biotech Hunter